{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T12:14:26Z","timestamp":1780402466322,"version":"3.54.1"},"reference-count":81,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.revmed.2026.03.441","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T11:45:27Z","timestamp":1776339927000},"page":"297-306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anticorps bisp\u00e9cifiques engageant les lymphocytes T pour le traitement des maladies auto-immunes\u00a0: \u00e9tat des lieux et perspectives th\u00e9rapeutiques"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4810-045X","authenticated-orcid":false,"given":"Marion","family":"Larue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beno\u00eet","family":"Ferment","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Allain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jehane","family":"Fadlallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baptiste","family":"Hervier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Arnulf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6734-413X","authenticated-orcid":false,"given":"Alexis","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.revmed.2026.03.441_bib0005","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/ni.1900","article-title":"Control systems and decision making for antibody production","volume":"11","author":"Goodnow","year":"2010","journal-title":"Nat Immunol"},{"issue":"5","key":"10.1016\/j.revmed.2026.03.441_bib0010","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0092-8674(00)80856-9","article-title":"Regulatory T cells: key controllers of immunologic self-tolerance","volume":"101","author":"Sakaguchi","year":"2000","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.revmed.2026.03.441_bib0015","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nri3667","article-title":"Positive and negative selection of the T cell repertoire: what thymocytes see and don\u2019t see","volume":"14","author":"Klein","year":"2014","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"10.1016\/j.revmed.2026.03.441_bib0020","doi-asserted-by":"crossref","first-page":"103811","DOI":"10.1016\/j.autrev.2025.103811","article-title":"Molecular\/antigenic mimicry and immunological cross-reactivity explains SARS-CoV-2-induced autoimmunity","volume":"24","author":"Adiguzel","year":"2025","journal-title":"Autoimmun Rev"},{"issue":"13","key":"10.1016\/j.revmed.2026.03.441_bib0025","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1096\/fasebj.12.13.1255","article-title":"Molecular mimicry and immune-mediated diseases","volume":"12","author":"Oldstone","year":"1998","journal-title":"FASEB J"},{"issue":"2","key":"10.1016\/j.revmed.2026.03.441_bib0030","doi-asserted-by":"crossref","first-page":"e1178","DOI":"10.1002\/iid3.1178","article-title":"Potential clinical implications of molecular mimicry-induced autoimmunity","volume":"12","author":"Suliman","year":"2024","journal-title":"Immun Inflamm Dis"},{"issue":"1","key":"10.1016\/j.revmed.2026.03.441_bib0035","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.cell.2014.03.011","article-title":"Role of the microbiota in immunity and inflammation","volume":"157","author":"Belkaid","year":"2014","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.revmed.2026.03.441_bib0040","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3109\/08916934.2015.1134511","article-title":"Epigenetic alterations underlying autoimmune diseases","volume":"49","author":"Aslani","year":"2016","journal-title":"Autoimmunity"},{"issue":"3","key":"10.1016\/j.revmed.2026.03.441_bib0045","doi-asserted-by":"crossref","first-page":"e1290037","DOI":"10.1080\/2162402X.2017.1290037","article-title":"Obinutuzumab-mediated high-affinity ligation of Fc\u03b3RIIIA\/CD16\u00a0primes NK cells for IFN\u03b3 production","volume":"6","author":"Capuano","year":"2017","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.revmed.2026.03.441_bib0050","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s13317-017-0100-y","article-title":"Next-generation anti-CD20\u00a0monoclonal antibodies in autoimmune disease treatment","volume":"8","author":"Du","year":"2017","journal-title":"Autoimmun Highlights"},{"issue":"14","key":"10.1016\/j.revmed.2026.03.441_bib0055","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1182\/blood-2017-06-789578","article-title":"BAFF and CD4+ T cells are major survival factors for long-lived splenic plasma cells in a B-cell\u2013depletion context","volume":"131","author":"Thai","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.revmed.2026.03.441_bib0060","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1172\/JCI65689","article-title":"B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells","volume":"123","author":"Mah\u00e9vas","year":"2013","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.revmed.2026.03.441_bib0065","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1182\/blood-2002-07-2157","article-title":"Suppression of autoreactive T-cell response to glycoprotein IIb\/IIIa by blockade of CD40\/CD154\u00a0interaction: implications for treatment of immune thrombocytopenic purpura","volume":"101","author":"Kuwana","year":"2003","journal-title":"Blood"},{"issue":"589","key":"10.1016\/j.revmed.2026.03.441_bib0070","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc3961","article-title":"Rituximab-resistant splenic memory B cells and newly engaged naive B cells fuel relapses in patients with immune thrombocytopenia","volume":"13","author":"Crickx","year":"2021","journal-title":"Sci Transl Med"},{"issue":"12","key":"10.1016\/j.revmed.2026.03.441_bib0075","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1056\/NEJMoa2409712","article-title":"Inebilizumab for treatment of IgG4-related disease","volume":"392","author":"Stone","year":"2025","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.revmed.2026.03.441_bib0080","doi-asserted-by":"crossref","first-page":"e163030","DOI":"10.1172\/jci.insight.163030","article-title":"A randomized, phase II study of sequential belimumab and rituximab in primary Sj\u00f6gren's syndrome","volume":"7","author":"Mariette","year":"2022","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.revmed.2026.03.441_bib0085","doi-asserted-by":"crossref","first-page":"e001424","DOI":"10.1136\/lupus-2024-001424","article-title":"Long-term safety and efficacy of the combination of belimumab and rituximab in the treatment of severe and refractory SLE: a preliminary report","volume":"12","author":"van Schaik","year":"2025","journal-title":"Lupus Sci Med"},{"issue":"15","key":"10.1016\/j.revmed.2026.03.441_bib0090","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2414719","article-title":"A phase 3\u00a0trial of telitacicept for systemic lupus erythematosus","volume":"393","author":"van Vollenhoven","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.revmed.2026.03.441_bib0095","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1136\/ard-2023-224854","article-title":"Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomized, double-blind, placebo-controlled trial","volume":"83","author":"Wu","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.revmed.2026.03.441_bib0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000492237","article-title":"Efficacy and safety of telitacicept in IgA nephropathy: a retrospective, multicenter study","volume":"149","author":"Liu","year":"2025","journal-title":"Nephron"},{"issue":"6","key":"10.1016\/j.revmed.2026.03.441_bib0105","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/bjh.18582","article-title":"Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: a phase 3, placebo-controlled, double-blind, parallel-group study","volume":"200","author":"Kuwana","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2026.03.441_bib0110","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1146\/annurev.med.57.042905.122625","article-title":"Bortezomib: proteasome inhibition as an effective anticancer therapy","volume":"57","author":"Richardson","year":"2006","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.revmed.2026.03.441_bib0115","doi-asserted-by":"crossref","first-page":"102724","DOI":"10.1016\/j.bcmd.2023.102724","article-title":"Daratumumab as a novel treatment option in refractory immune thrombocytopenia","volume":"99","author":"Vernava","year":"2023","journal-title":"Blood Cells Mol Dis"},{"issue":"4","key":"10.1016\/j.revmed.2026.03.441_bib0120","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.revmed.2026.03.441_bib0125","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies\u00a0\u2014\u00a0BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.revmed.2026.03.441_bib0130","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.revmed.2026.03.441_bib0135","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/j.apsb.2024.03.027","article-title":"Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy","volume":"14","author":"Qin","year":"2024","journal-title":"Acta Pharm Sin B"},{"issue":"6","key":"10.1016\/j.revmed.2026.03.441_bib0140","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.revmed.2026.03.441_bib0145","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3324\/haematol.2019.230128","article-title":"Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party","volume":"106","author":"Henes","year":"2021","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.revmed.2026.03.441_bib0150","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","article-title":"Advancements and challenges in CAR T-cell therapy in autoimmune diseases","volume":"20","author":"Schett","year":"2024","journal-title":"Nat Rev Rheumatol"},{"issue":"16","key":"10.1016\/j.revmed.2026.03.441_bib0155","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3390\/cells14161242","article-title":"Chimeric antigen receptor T cell immunotherapy for autoimmune rheumatic disorders: where are we now?","volume":"14","author":"Anyfanti","year":"2025","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.revmed.2026.03.441_bib0160","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41577-024-01035-3","article-title":"Chimeric antigen receptor T cell therapy for autoimmune disease","volume":"24","author":"Chung","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.revmed.2026.03.441_bib0165","doi-asserted-by":"crossref","first-page":"1613878","DOI":"10.3389\/fimmu.2025.1613878","article-title":"CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon","volume":"16","author":"Wu","year":"2025","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.revmed.2026.03.441_bib0170","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1016\/j.ymthe.2024.12.018","article-title":"Targeting human plasma cells using regulated BCMA CAR T cells eliminates circulating antibodies in humanized mice","volume":"33","author":"Honaker","year":"2025","journal-title":"Mol Ther"},{"issue":"13","key":"10.1016\/j.revmed.2026.03.441_bib0175","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.revmed.2026.03.441_bib0180","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1182\/blood-2024-206155","article-title":"Risk of infections in multiple myeloma patients treated with bispecific antibodies","volume":"144","author":"Cani","year":"2024","journal-title":"Blood"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.revmed.2026.03.441_bib0185","doi-asserted-by":"crossref","first-page":"6671","DOI":"10.1182\/blood-2023-173893","article-title":"The role of intravenous immunoglobulin (IVIG) in reducing infection risk in multiple myeloma patients receiving immune-based therapies: a single-center experience","volume":"142","author":"Lim","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.revmed.2026.03.441_bib0190","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/bloodadvances.2023011658","article-title":"Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation","volume":"8","author":"Frerichs","year":"2024","journal-title":"Blood Adv"},{"issue":"16","key":"10.1016\/j.revmed.2026.03.441_bib0195","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood.2023022432","article-title":"Consensus recommendations on the management of toxicity associated with CD3\u00d7CD20\u00a0bispecific antibody therapy","volume":"143","author":"Crombie","year":"2024","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.revmed.2026.03.441_bib0200","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood.2021011994","article-title":"Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities","volume":"141","author":"Falchi","year":"2023","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.revmed.2026.03.441_bib0205","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1182\/blood-2010-01-263533","article-title":"Antigenic modulation limits the efficacy of anti-CD20\u00a0antibodies: implications for antibody selection","volume":"115","author":"Beers","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.revmed.2026.03.441_bib0210","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.ard.2025.06.2120","article-title":"Effects of different B-cell-depleting strategies on the lymphatic tissue","volume":"84","author":"Tur","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.revmed.2026.03.441_bib0215","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/ard-2024-226142","article-title":"CD19-CAR T-cell therapy induces deep tissue depletion of B cells","volume":"84","author":"Tur","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.revmed.2026.03.441_bib0220","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/cei\/uxae031","article-title":"Disrupting B- and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy?","volume":"217","author":"Shah","year":"2024","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"10.1016\/j.revmed.2026.03.441_bib0225","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/art.42784","article-title":"CD19\u00a0chimeric antigen receptor T cell treatment: unraveling the role of B cells in systemic lupus erythematosus","volume":"76","author":"Taubmann","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"10416","key":"10.1016\/j.revmed.2026.03.441_bib0230","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.revmed.2026.03.441_bib0235","first-page":"345","article-title":"Selective depletion of B-cell subsets underlies increased risk of infection in multiple myeloma patients treated with anti-BCMA vs. GPRC5D bispecific antibodies","volume":"146","author":"Jelinek","year":"2025","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.revmed.2026.03.441_bib0240","doi-asserted-by":"crossref","first-page":"5479","DOI":"10.1182\/bloodadvances.2023012522","article-title":"Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in multiple myeloma","volume":"8","author":"Palacios-Berraquero","year":"2024","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.revmed.2026.03.441_bib0245","first-page":"1345","article-title":"A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T-cell therapy in multiple myeloma","volume":"43","author":"Rade","year":"2025","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.revmed.2026.03.441_bib0250","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1182\/bloodadvances.2023012047","article-title":"Economic evaluation: immunoglobulin versus prophylactic antibiotics in hypogammaglobulinemia and hematological malignancies","volume":"8","author":"Carrillo de Albornoz","year":"2024","journal-title":"Blood Adv"},{"issue":"Suppl.\u00a02","key":"10.1016\/j.revmed.2026.03.441_bib0255","first-page":"A1187","article-title":"ATG-201, a novel \u201c2+1\u201d CD19-targeted T-cell engager for the treatment of B-cell malignancies and B-cell\u2013related autoimmune diseases","volume":"12","author":"Bian","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.revmed.2026.03.441_bib0260","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood.2023022937","article-title":"Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series","volume":"143","author":"Forgeard","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.revmed.2026.03.441_bib0265","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/bjh.19960","article-title":"Update on B-cell maturation antigen\u2013directed therapies in AL amyloidosis","volume":"206","author":"Jamroziak","year":"2025","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.revmed.2026.03.441_bib0270","first-page":"287606","article-title":"Teclistamab for heavily pretreated relapsed\/refractory POEMS syndrome","volume":"110","author":"Talbot","year":"2025","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.revmed.2026.03.441_bib0275","first-page":"1891","article-title":"Teclistamab therapy for refractory type 1\u00a0cryoglobulinemia","volume":"110","author":"Battaglini","year":"2025","journal-title":"Haematologica"},{"issue":"Suppl.\u00a09","key":"10.1016\/j.revmed.2026.03.441_bib0280","first-page":"L12","article-title":"A-319, a CD3\u00d7CD19\u00a0T-cell engager (TCE) for the treatment of severe\/refractory systemic lupus erythematosus: early evidence of rapid reset of disease-specific autoimmunity [abstract]","volume":"76","author":"Mei","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"482","key":"10.1016\/j.revmed.2026.03.441_bib0285","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B-cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.revmed.2026.03.441_bib0290","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1515\/rir-2024-0029","article-title":"Therapeutic potential of CD20\/CD3\u00a0bispecific antibodies in the treatment of autoimmune diseases","volume":"5","author":"Huang","year":"2025","journal-title":"Rheumatol Immunol Res"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.revmed.2026.03.441_bib0295","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1182\/blood-2019-131650","article-title":"High-avidity IgM-based CD20\u00d7CD3\u00a0bispecific antibody (IGM-2323) for enhanced T-cell\u2013dependent killing with minimal cytokine release","volume":"134","author":"Baliga","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.revmed.2026.03.441_bib0300","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/s41591-024-02964-1","article-title":"Bispecific T-cell engager therapy for refractory rheumatoid arthritis","volume":"30","author":"Bucci","year":"2024","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.revmed.2026.03.441_bib0305","doi-asserted-by":"crossref","first-page":"e70252","DOI":"10.1111\/1756-185X.70252","article-title":"A bite of B cells: the potential role of bispecific T-cell engager therapy (BiTE) in autoimmune diseases","volume":"28","author":"Zheng","year":"2025","journal-title":"Int J Rheum Dis"},{"issue":"9","key":"10.1016\/j.revmed.2026.03.441_bib0310","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1056\/NEJMc2407150","article-title":"Teclistamab-induced remission in refractory systemic lupus erythematosus","volume":"391","author":"Alexander","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.revmed.2026.03.441_bib0315","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1056\/NEJMc2408786","article-title":"BCMA-targeted T-cell engager therapy for autoimmune disease","volume":"391","author":"Hagen","year":"2024","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.revmed.2026.03.441_bib0320","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJMc2506740","article-title":"BCMA T-cell engager therapy in patients with refractory autoimmune disease","volume":"393","author":"Bucci","year":"2025","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.revmed.2026.03.441_bib0325","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1182\/bloodadvances.2023010539","article-title":"Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis","volume":"7","author":"Reynolds","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.revmed.2026.03.441_bib0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-024-46321-9","article-title":"Human IgG Fc engineering for enhanced plasma half-life, mucosal distribution, and killing of cancer cells and bacteria","volume":"15","author":"Foss","year":"2024","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.revmed.2026.03.441_bib0335","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1039\/C9MD00018F","article-title":"Noncovalent albumin-binding ligands for extending the circulating half-life of small biotherapeutics","volume":"10","author":"Zorzi","year":"2019","journal-title":"Medchemcomm"},{"issue":"8","key":"10.1016\/j.revmed.2026.03.441_bib0340","doi-asserted-by":"crossref","first-page":"e007398","DOI":"10.1136\/jitc-2023-007398","article-title":"CLN-978, a novel half-life\u2013extended CD19\/CD3\/HSA-specific T-cell\u2013engaging antibody construct with potent activity against B-cell malignancies with low CD19\u00a0expression","volume":"11","author":"Meetze","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.revmed.2026.03.441_bib0345","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1080\/19420862.2016.1210747","article-title":"Fab-dsFv: a bispecific antibody format with extended serum half-life through albumin binding","volume":"8","author":"Dav\u00e9","year":"2016","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.revmed.2026.03.441_bib0350","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/abt\/tbad027","article-title":"Next generation of multispecific antibody engineering","volume":"7","author":"Keri","year":"2024","journal-title":"Antibody Ther"},{"issue":"5","key":"10.1016\/j.revmed.2026.03.441_bib0355","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1074\/jbc.M116.748707","article-title":"Biological characterization of a stable effector functionless (SEFL) monoclonal antibody scaffold in vitro","volume":"292","author":"Liu","year":"2016","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.revmed.2026.03.441_bib0360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-93842-0","article-title":"Generation of T-cell\u2013redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3\u00a0affinity tuning","volume":"11","author":"Haber","year":"2021","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.revmed.2026.03.441_bib0365","doi-asserted-by":"crossref","first-page":"e002488","DOI":"10.1136\/jitc-2021-002488","article-title":"Attenuating CD3\u00a0affinity in a PSMA\u00d7CD3\u00a0bispecific antibody enables killing of prostate tumor cells with reduced cytokine release","volume":"9","author":"Dang","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.revmed.2026.03.441_bib0370","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s41232-016-0015-4","article-title":"BAFF- and APRIL-targeted therapy in systemic autoimmune diseases","volume":"36","author":"Nakayamada","year":"2016","journal-title":"Inflamm Regen"},{"issue":"1","key":"10.1016\/j.revmed.2026.03.441_bib0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13063-022-06874-w","article-title":"Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2\u00a0trial","volume":"23","author":"van Schaik","year":"2022","journal-title":"Trials"},{"issue":"9","key":"10.1016\/j.revmed.2026.03.441_bib0380","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.3390\/cimb44090261","article-title":"Synthetic TGF-\u03b2 signaling agonist-treated dendritic cells induce tolerogenicity and antirheumatic effects","volume":"44","author":"Oh","year":"2022","journal-title":"Curr Issues Mol Biol"},{"key":"10.1016\/j.revmed.2026.03.441_bib0385","doi-asserted-by":"crossref","first-page":"113842","DOI":"10.1016\/j.jconrel.2025.113842","article-title":"Sustained codelivery of heat shock protein peptide and rapamycin via nano-in-hydrogel induces immune tolerance in rheumatoid arthritis","volume":"383","author":"Cao","year":"2025","journal-title":"J Control Release"},{"key":"10.1016\/j.revmed.2026.03.441_bib0390","doi-asserted-by":"crossref","first-page":"1335998","DOI":"10.3389\/fimmu.2024.1335998","article-title":"Bi-specific autoantigen-T-cell engagers as targeted immunotherapy for autoreactive B-cell depletion in autoimmune diseases","volume":"15","author":"Perico","year":"2024","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.revmed.2026.03.441_bib0395","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/cpt.2929","article-title":"Pharmacokinetics and pharmacokinetic\/pharmacodynamic properties of rozibafusp alfa, a bispecific inhibitor of BAFF and ICOSL: analyses of phase I clinical trials","volume":"114","author":"Abuqayyas","year":"2023","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.revmed.2026.03.441_bib0400","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s43018-019-0004-z","article-title":"Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T-cell receptor co-stimulation","volume":"1","author":"Wu","year":"2020","journal-title":"Nat Cancer"},{"issue":"1","key":"10.1016\/j.revmed.2026.03.441_bib0405","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-023-01482-w","article-title":"Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies","volume":"16","author":"Tapia-Galisteo","year":"2023","journal-title":"J Hematol Oncol"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866326005278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866326005278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T11:57:42Z","timestamp":1780401462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866326005278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":81,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0248866326005278"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2026.03.441","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticorps bisp\u00e9cifiques engageant les lymphocytes T pour le traitement des maladies auto-immunes\u00a0: \u00e9tat des lieux et perspectives th\u00e9rapeutiques","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2026.03.441","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}